Biocon net profit falls 26 percent to Rs 167.8 crore in Q1

Published On 2020-07-26 04:15 GMT   |   Update On 2020-07-26 04:15 GMT

Bengaluru: Biotechnology major Biocon has reported a 26.30 percent decline in its consolidated net profit at Rs 167.8 crore for the quarter ended June 30, 2020 mainly on account of higher R&D spend and lower profitability in the Research Services segment.The company had posted a net profit of Rs 227.7 crore for the corresponding period of the previous fiscal, Biocon said in a...

Login or Register to read the full article

Bengaluru: Biotechnology major Biocon has reported a 26.30 percent decline in its consolidated net profit at Rs 167.8 crore for the quarter ended June 30, 2020 mainly on account of higher R&D spend and lower profitability in the Research Services segment.

The company had posted a net profit of Rs 227.7 crore for the corresponding period of the previous fiscal, Biocon said in a late-night filing to the BSE.

Consolidated revenue from operations of the company stood at Rs 1,671.3 crore for the quarter under consideration, as against Rs 1,458.9 crore for the same period year ago, it added.

Read Also: Biocon Biologics, Voluntis collaborate for digital therapeutics for diabetics patients

"Profitability for the quarter was impacted due to higher research and development (R&D) spend, lower profit share in the Biosimilars business, and lower profitability in the Research Services segment," Biocon Executive Chairperson Kiran Mazumdar-Shaw said.

It has been a breakthrough quarter for Biocon as it made a significant contribution to the global efforts aimed at addressing the pandemic through its innovative science, she added.

Research and development spend for the quarter stood at Rs 142 crore, as against Rs 110 crore for the year-ago quarter, Biocon said.

Shares of Biocon Ltd were trading at Rs 418.85 per scrip on BSE, down 2.66 percent from its previous close.

Read Also: Biocon Itolizumab gets DCGI nod to treat COVID-19 patients

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News